Nbw Capital LLC Abb Vie Inc. Transaction History

Nbw Capital LLC

$510 Million
Q3 2024

A detailed history of Nbw Capital LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Nbw Capital LLC holds 39,518 shares of ABBV stock, worth $7.08 Million. This represents 1.53% of its overall portfolio holdings.

Number of Shares

39,518

Previous 38,682 2.16%

Holding current value

$7.08 Million

Previous $6.63 Million 17.64%

% of portfolio

1.53%

Previous 1.33%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 04, 2024	BUY	$163.84 - $199.33 $136,970 - $166,639	836 Added 2.16%	39,518 $7.8 Million
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $5.52 Million - $6.44 Million	35,631 Added 1167.85%	38,682 $6.63 Million
Q1 2024 Jun 13, 2024	BUY	$159.82 - $182.1 $2,077 - $2,367	13 Added 0.43%	3,051 $555,000
Q4 2023 Jan 31, 2024	SELL	$137.6 - $154.97 $33,849 - $38,122	-246 Reduced 7.49%	3,038 $470,000
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $20,305 - $23,506	152 Added 4.85%	3,284 $489,000
Q2 2023 Aug 15, 2023	BUY	$132.51 - $164.9 $23,719 - $29,517	179 Added 6.06%	3,132 $421,000
Q1 2023 May 11, 2023	BUY	$144.61 - $166.54 $144 - $166	1 Added 0.03%	2,953 $470,000
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $33,471 - $40,140	242 Added 8.93%	2,952 $477,000
Q3 2022 Nov 03, 2022	BUY	$134.21 - $153.93 $363,709 - $417,150	2,710 New	2,710 $364,000
Q2 2022 Aug 01, 2022	SELL	$137.62 - $174.96 $179,594 - $228,322	-1,305 Closed	0 $0
Q1 2022 May 04, 2022	SELL	$131.98 - $163.75 $30,619 - $37,990	-232 Reduced 15.09%	1,305 $212,000
Q4 2021 Feb 03, 2022	BUY	$107.43 - $135.93 $165,119 - $208,924	1,537 New	1,537 $208,000

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $317B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nbw Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nbw Capital LLC with notifications on news.

Account